Abdulkader Puranwala

Hi, sir. Thank you for the opportunity. The first question is in relation to your India business. So, I heard that you have added few MRs this year, and what will be the quantum of MR addition for the next year?

Okay. Sir, when we talked about last quarter and this quarter as well about foraying into two new therapeutic categories, just wanted to understand from a prescriber standpoint, so the MRs are currently catering to the same prescriber ?

Understood. Understood. And one more on your Africa institution business, I know that you have been quite cautious from the outlook of this business for quite some time. But given the recent uncertainties about donor funding, though not directly related to your line of business, but any outlook you may like to provide on that front would be helpful. Thank you.